| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 4025879 | Ophthalmology | 2015 | 7 Pages |
Abstract
Bevacizumab and ranibizumab had equivalent effects on visual acuity at 1 year when administered according to a treat-and-extend protocol. The visual acuity results at 1 year were comparable to those of other clinical trials with monthly treatment. The numbers of serious adverse events were small.
Keywords
CrtAMDPRNETDRSBCVAfluorescein angiographyOctbest-corrected visual acuityOptical coherence tomographyearly treatment diabetic retinopathy studyage-related macular degenerationcentral retinal thicknesspro re nataconfidence intervalVascular endothelial growth factorVascular Endothelial Growth Factor (VEGF)
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Karina MD, Terje R. MD, PhD, Leiv PhD, Ragnheiður MD, PhD,